We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Test for TB Could Eliminate Unnecessary Treatment

By LabMedica International staff writers
Posted on 25 Jun 2014
A new screening process for tuberculosis (TB) infections in Canadian prisons could mean that more than 50% of those screened will not undergo unnecessary treatment due to false positives.

A test for TB using interferon-gamma release assays (IGRA) will detect a preexisting TB infection, or latent TB, that might not present itself for many years, or until the body becomes weakened by another source. More...


A study group led by infectious disease experts from Queen’s University (Kingston, ON, Canada), tested inmates for TB at a Canadian intake institution before moving on to different corrections facilities. The scientists used both the tuberculosis skin test (TST) for TB which has been used for over 100 years but comes with two main limitations, and the IGRA. The TST requires two visits to determine the results: one to perform the test and then another visit a couple of days later to read the results and depending on the patient's exposure to other mycobacteria or the Bacille Calmette Guerin (BCG) vaccine, accordingly the TST test can give many false positives.

The IGRA tests cannot prove that latent TB infections will progress into active TB until the patient begins to show symptoms. Better tools to predict who will go on to develop active and potentially infectious TB are being actively pursued. The investigators found that 96 inmates tested positive for TB via the TST test, but only 31 of these inmates were confirmed as true latent TB infection when using the IGRA test.

Wendy L.Wobeser, MD, the study’s lead author said, “It is fairly uncommon that latent TB will reactivate, with only about a 10% chance. That said, given the crowding in corrections facilities, the mass exposure of inmates to TB could be disastrous. It is such a slow disease progression that it is hard for us to say with certainty who will actually go on to develop TB. I hope that this test will eventually be used in corrections and is able to reduce people who might otherwise be treated unnecessarily for latent TB.”

Ilan Schwartz, MD, a coauthor of the study said, “What I found surprising was just how much discordance there was between the TST and IGRA tests. Historically, all of those who tested TB-positive by the TST test would have been subjected to 12 months of drug treatments that can have considerable side effects.”

Related Links:

Queen’s University



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Rapid Molecular Testing Device
FlashDetect Flash10
New
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: EvoLiver is the first test to receive FDA Breakthrough Device Designation in five years in the liver cancer surveillance space (Photo courtesy of Mursla Bio)

Patient-Friendly Blood Test to Transform Liver Cancer Surveillance

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is the fastest-growing cause of cancer-related deaths. Although clinical guidelines recommend routine surveillance for high-risk... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.